Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COCRYSTAL PHARMA, INC.

(COCP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

COCRYSTAL PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/14/2021 | 04:33pm EDT

Item 7.01 Regulation FD Disclosure

Beginning at 1:00 a.m. ET on September 13, 2021, in connection with its senior management presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021, Cocrystal Pharma, Inc. (the "Company") is making available a webcast of the presentation on its website. A copy of the slide presentation is being furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits



Exhibit   Description

99.1        Cocrystal Pharma, Inc. Corporate Presentation, dated September 2021

104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)

© Edgar Online, source Glimpses

All news about COCRYSTAL PHARMA, INC.
09/14COCRYSTAL PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
09/07COCRYSTAL PHARMA : to Present at the H.C. Wainwright 23rd Annual Global Investment Confere..
AQ
08/16COCRYSTAL PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
08/16Cocrystal Pharma, Inc. Announces Earnings Results for the Second Quarter Ended June 30,..
CI
08/16COCRYSTAL PHARMA : Reports Second Quarter 2021 Financial Results and Provides Antiviral Pr..
AQ
07/30COCRYSTAL PHARMA : SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Acti..
AQ
07/29COCRYSTAL PHARMA : Says COVID Treatment Candidate May be Effective Against Delta, Gamma Va..
MT
07/29COCRYSTAL PHARMA : SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Acti..
AQ
07/29Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum A..
CI
07/20COCRYSTAL PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on COCRYSTAL PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -10,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,18x
Yield 2021 -
Capitalization 102 M 102 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 85,3x
Nbr of Employees 13
Free-Float 82,2%
Chart COCRYSTAL PHARMA, INC.
Duration : Period :
Cocrystal Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COCRYSTAL PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,05 $
Average target price 4,50 $
Spread / Average Target 329%
EPS Revisions
Managers and Directors
Sam Lee President & Co-Chief Executive Officer
James Joseph Martin Co-Chief Executive Officer, CFO & Secretary
Roger David Kornberg Chairman
Phillip Frost Independent Director
Steven D. Rubin Vice Chairman